Browse EFEMP1

Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space Secreted, extracellular space, extracellular matrix Note=Localizes to the lamina propria underneath the olfactory epithelium.
Domain PF12662 Complement Clr-like EGF-like
PF07645 Calcium-binding EGF domain
Function

Binds EGFR, the EGF receptor, inducing EGFR autophosphorylation and the activation of downstream signaling pathways. May play a role in cell adhesion and migration. May function as a negative regulator of chondrocyte differentiation. In the olfactory epithelium, it may regulate glial cell migration, differentiation and the ability of glial cells to support neuronal neurite outgrowth.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001654 eye development
GO:0002062 chondrocyte differentiation
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007423 sensory organ development
GO:0007601 visual perception
GO:0009791 post-embryonic development
GO:0009886 post-embryonic animal morphogenesis
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0032330 regulation of chondrocyte differentiation
GO:0032331 negative regulation of chondrocyte differentiation
GO:0038127 ERBB signaling pathway
GO:0043010 camera-type eye development
GO:0048048 embryonic eye morphogenesis
GO:0048050 post-embryonic eye morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048563 post-embryonic animal organ morphogenesis
GO:0048568 embryonic organ development
GO:0048569 post-embryonic animal organ development
GO:0048592 eye morphogenesis
GO:0050953 sensory perception of light stimulus
GO:0051216 cartilage development
GO:0061035 regulation of cartilage development
GO:0061037 negative regulation of cartilage development
GO:0061448 connective tissue development
GO:0090596 sensory organ morphogenesis
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005006 epidermal growth factor-activated receptor activity
GO:0005154 epidermal growth factor receptor binding
GO:0008083 growth factor activity
GO:0019199 transmembrane receptor protein kinase activity
GO:0070851 growth factor receptor binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1566948: Elastic fibre formation
R-HSA-1474244: Extracellular matrix organization
R-HSA-2129379: Molecules associated with elastic fibres
Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EFEMP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EFEMP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EFEMP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6650.236
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6050.725
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6820.482
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2850.469
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6760.743
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2090.936
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3170.647
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3340.836
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2180.907
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.320.575
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.9050.367
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6560.0117
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EFEMP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277305.5-5.50.572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275906.8-6.80.304
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EFEMP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EFEMP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EFEMP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EFEMP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EFEMP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EFEMP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEFEMP1
NameEGF containing fibulin-like extracellular matrix protein 1
Aliases S1-5; FBLN3; MTLV; fibulin 3; DHRD; FBNL; fibrillin-like; EGF-containing fibulin-like extracellular matrix p ......
Chromosomal Location2p16
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EFEMP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.